Trials / Recruiting
RecruitingNCT04149743
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure [HATS-OFF]
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 420 (estimated)
- Sponsor
- Aventusoft, LLC. · Industry
- Sex
- All
- Age
- 22 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the HEMOTAG® system in a less controlled environment and concurrently develop the system for use by patients with heart failure.
Detailed description
The overall objective of research is to test, adapt, refine and validate the HEMOTAG® system to be used outside the usual medical care environments to reduce hospital readmissions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Standard of Care with Hemotag | Comparison of outcomes |
Timeline
- Start date
- 2022-01-31
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2019-11-04
- Last updated
- 2024-08-21
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04149743. Inclusion in this directory is not an endorsement.